X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and reduces hyperglycemia and obesity in db/db mice

Molecular and Cellular Endocrinology

Volumn 405, Issue , 2015, Pages 63-73

  Han, Jun ^a   Yi, Jia ^a   Liang, Fengying ^a   Jiang, Bo ^a   Xiao, Ying ^a   Gao, Shouhong ^a   Yang, Na ^a   Hu, Honggang ^b   Xie, Wei Fen ^a   Chen, Wansheng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Animal experiment; Anti diabetic; Compounds

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MANGIFERIN; MANGIFERIN DERIVATIVE; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; X 3; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; PROPIONIC ACID DERIVATIVE; X-3 XANTHONE COMPOUND; XANTHONE DERIVATIVE;

3T3 CELL LINE; ACUTE TOXICITY; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DB/DB MOUSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOTHALAMUS; LIVER; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; LD50; MALE; METABOLISM; MOUSE MUTANT;

3T3-L1 CELLS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; LETHAL DOSE 50; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; ORGAN SPECIFICITY; PROPIONATES; XANTHONES;

EID: 84923199386     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.02.008     Document Type: Article

References (49)

1. Atkinson L.L., Kozak R., Kelly S.E., et al. Potential mechanisms and consequences of cardiactriacylglycerol accumulation in insulin-resistant rats. Am. J. Physiol. Endocrinol. Metab 2003, 284:E923-E930.
2. Badr M.Z. PPAR research: successful launching and promising future. PPAR Res 2009, 543584-543586.
3. Beauloye C., Marsin A.S., Bertrand L., et al. The stimulation of heart glycolysis by increased workload does not require AMP-activated protein kinase but a wortmannin-sensitive mechanism. FEBS Lett 2002, 531:324-328.
4. Cai F., Xu W., Wei H., et al. Simultaneous determination of active xanthone glycosides, timosaponins and alkaloids in rat plasma after oral administration of Zi-Shen Pill extract for the pharmacokinetic study by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2010, 878:1845-1854.
5. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci 2004, 29:18-24.
6. Carling D., Zammit V.A., Hardie D.G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 1987, 223:217-222.
7. Ceriello A., Johns D., Widel M., et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005, 28:266-272.
8. Choi S.S., Cha B.Y., Lee Y.S., et al. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci 2009, 84(25-26):908-914. 10.1016/j.lfs.2009.04.001.
9. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6825-6830.
10. Fryer L.G., Parbu-Patel A., Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem 2002, 277:25226-25232.
11. Guo F., Huang C., Liao X., et al. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res 2011, 55:1809-1818.
12. Hardie D.G., Hawley S.A., Scott J.W. AMP-activated protein kinase: development of the energy sensor concept. J. Physiol 2006, 574:7-15.
13. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
14. Hirosumi J., Tuncman G., Chang L., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
15. Hue L., Beauloye C., Marsin A.S., et al. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J. Mol. Cell. Cardiol 2002, 34:1091-1097.
16. Ichiki H., Miura T., Kubo M., et al. New antidiabetic compounds, mangiferin and its glucoside. Biol. Pharm. Bull 1998, 21:1389-1390.
17. Janjetovic K., Vucicevic L., Misirkic M., et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur. J. Pharmacol 2011, 651:41-50.
18. Jing M., Ismail-Beigi F. Role of 5'-AMP-activated protein kinase in stimulation of glucose transport in response to inhibition of oxidative phosphorylation. Am. J. Physiol. Cell Physiol 2006, 290:484-491.
19. Jones J.P., Dohm G.L. Regulation of glucose transporter GLUT-4 and hexokinase II gene transcription by insulin and epinephrine. Am. J. Physiol. Endocrinol. Metab 1997, 273:E682-E687.
20. Jung U.J., Lee M.K., Park Y.B., et al. Antihyperglycemic and antioxidant properties of caffeic acid in db/db mice. J. Pharmacol. Exp. Ther 2006, 318(2):476-483.
21. Kubota N., Terauchi Y., Miki H., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4:597-609.
22. Lansey M.N., Walker N.N., Hargett S.R., et al. Deletion of Rab GAP AS160 modifies glucose uptake and GLUT4 translocation in primary skeletal muscles and adipocytes and impairs glucose homeostasis. Am. J. Physiol. Endocrinol. Metab 2012, 303:E1273-E1286.
23. Li X., Cui X., Sun X., et al. Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Phytother. Res 2010, 24(6):893-899.
24. Lochhead P.A., Salt I.P., Walker K.S., et al. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000, 49:896-903.
25. McGarry J.D., Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem 1997, 244:1-14.
26. Mezei O., Banz W.J., Steger R.W., et al. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J. Nutr 2003, 133:1238-1243.
27. Miura T., Ichiki H., Hashimoto I., et al. Antidiabetic activity of a xanthone compound, mangiferin. Phytomedicine 2001, 8:85-87.
28. Mu J., Brozinick J.T., Valladares O., et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 2001, 7:1085-1094.
29. Muruganandan S., Gupta S., Kataria M., et al. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002, 176:165-173.
30. Muruganandan S., Srinivasan K., Gupta S., et al. Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J. Ethnopharmacol 2005, 97:497-501.
31. Nawrocki A.R., Rajala M.W., Tomas E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem 2010, 281:2654-2660.
32. Niu Y., Li S., Na L., et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS ONE 2012, 7:e30782.
33. Sakoda H., Ogihara T., Anai M., et al. Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. Am. J. Physiol. Endocrinol. Metab 2002, 282:E1239-E1244.
34. Sanders M.J., Ali Z.S., Hegarty B.D., et al. Defining the mechanism of activation of AMP-activated protein kinase by the small moleculeA-769662, a member of the thienopyridone family. J. Biol. Chem 2007, 282:32539-32548.
35. Sano H., Eguez L., Teruel M.N., et al. Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab 2007, 5(4):293-303.
36. Schernthaner G., Matthews D.R., Charbonnel B., et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab 2004, 89:6068-6076.
37. Shaw R.J., Lamia K.A., Vasquez D., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310(5754):1642-1646.
38. Sirtris Pharmaceuticals Sirtris announces SRT501 lowers glucose in twice-daily dosing clinical trial 2008, Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics" (Press release). April 17, accessed 9.08.10.
39. Sirtris Pharmaceuticals Sirtris continues to lead the way in resveratrol based research. My Resveratrol Experience 2009, 10.04; accessed 22.01.11.
40. Sun Y., Connors K.E., Yang D.Q. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol. Cell. Biochem 2007, 306:239-245.
41. Tetko I.V., Poda G., Ostermann C., et al. Large-scale evaluation of log P predictors: local corrections may compensate insufficient accuracy and need of experimentally testing every other compound. Chem. Biodivers 2009, 6:1837-1844. 10.1002/cbdv.200900075.
42. Viollet B., Andreelli F., Jorgensen S.B., et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest 2003, 111:91-98.
43. Viollet B., Foretz M., Guigas B., et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol 2006, 574:41-53.
44. Viollet B., Lantier L., Devin-Leclerc J., et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front. Biosci 2009, 14:3380-3400.
45. Wang C., Mao X., Wang L., et al. Adiponectin sensitizes insulin signaling by reducing p70S6 kinase-mediated serine phosphorylation of IRS-1. J. Biol. Chem 2007, 282:7991-7996.
46. Yoshikawa M., Nishida N., Shimoda H., et al. Polyphenol constituents from salacia species: quantitative analysis of mangiferin with α-glucosidase and aldose reductase inhibitory activities. Yakugaku Zasshi 2001, 121:371-378.
47. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9:407-416.
48. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest 2001, 108:1167-1174.
49. Zou M.H., Hou X.Y., Shi C.M., et al. Activation of 5'-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells: role of peroxynitrite. J. Biol. Chem 2003, 278:34003-34010.